Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling

Wang,Mingyi; Ma,Xiangdong; Wang,Jian; Wang,Lin; Wang,Yu

doi:10.3892/ijo.2014.2301

Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling

Authors:
- Mingyi Wang
- Xiangdong Ma
- Jian Wang
- Lin Wang
- Yu Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, General Hospital of the People's Liberation Army, Chengdu Military Region, P.R. China, Department of Obstetrics and Gynecology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, P.R. China
Published online on: February 14, 2014 https://doi.org/10.3892/ijo.2014.2301
Pages: 1401-1409

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Notch signaling is implicated in ovarian cancer tumorigenesis and inhibition of Notch signaling with γ-secretase inhibitor DAPT resulted in reduction of tumor cell viability and induction of apoptosis in ovarian cancer cells. This study investigated whether DAPT has the same effect on ovarian cancer cells that are resistant to cisplatin and the underlying molecular events. Ovarian cancer cell lines resistant to cisplatin were treated with DAPT, cisplatin or combination for cell viability MTT, flow cytometric cell cycle, ELISA apoptosis and colony formation assays. qRT-PCR and western blotting were used to detect gene expressions. We found that pretreatment of ovarian cancer cisplatin-resistant cell lines with DAPT for 24 h and then with cisplatin for 72 h showed a synergistic antitumor activity in these cell lines, while cisplatin treatment and then addition of DAPT just showed an additive or antagonistic effects on these cisplatin-resistant ovarian cancer cells. Moreover, pretreatment of ovarian cancer cell lines with DAPT and then with cisplatin also inhibited tumor cell colony formation capacity, arrested tumor cells at G2 phase of the cell cycle and induced apoptosis. The cell cycle and apoptosis-related genes, such as cyclin B1, Bcl-2 and caspase-3, were also modulated by the treatment. Pretreatment of ovarian cancer cell lines with DAPT and then with cisplatin downregulated Notch1 and Hes1 expression dose- and time-dependently. The current data demonstrate that DAPT pretreatment was able to sensitize cisplatin-resistant human ovarian cancer cells to cisplatin by downregulation of Notch signaling.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2.	McGuire WP III and Markman M: Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer. 89(Suppl 3): S3–S8. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Stewart JJ, White JT, Yan X, et al: Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics. 5:433–443. 2006. View Article : Google Scholar
4.	Mellish KJ, Barnard CF, Murrer BA and Kelland LR: DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer. 62:717–723. 1995. View Article : Google Scholar : PubMed/NCBI
5.	O’Neill CF, Koberle B, Masters JR and Kelland LR: Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer. 81:1294–1303. 1999.
6.	Ohmichi M, Hayakawa J, Tasaka K, Kurachi H and Murata Y: Mechanisms of platinum drug resistance. Trends Pharmacol Sci. 26:113–116. 2005. View Article : Google Scholar
7.	Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69:2400–2407. 2009. View Article : Google Scholar
8.	Meng RD, Shelton CC, Li YM, et al: gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 69:573–582. 2009. View Article : Google Scholar
9.	Kuroda Y, Murakami N, Morota M, et al: Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. J Radiat Res. 53:588–593. 2012. View Article : Google Scholar : PubMed/NCBI
10.	Lai EC: Notch signaling: control of cell communication and cell fate. Development. 131:965–973. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: cell fate control and signal integration in development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
12.	Nickoloff BJ, Osborne BA and Miele L: Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 22:6598–6608. 2003. View Article : Google Scholar
13.	Suwannarurk K, Bhamarapravatana K, Thaweekul Y, Mairaing K, Poomtavorn Y and Pattaraarchachai J: A 1-year experience with liquid-based and conventional papanicolaou smear in Thammasat University Hospital. J Med Assoc Thai. 94(Suppl 7): S47–S51. 2011.PubMed/NCBI
14.	Wagner U, Marth C, Largillier R, et al: Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 107:588–591. 2012. View Article : Google Scholar
15.	Doll CM, Aquino-Parsons C, Pintilie M, et al: The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis. Int J Radiat Oncol Biol Phys. 85:721–727. 2013. View Article : Google Scholar
16.	Miyamura T, Masuzaki H and Ishimaru T: Conservative treatment of a cervical pregnancy with local methotrexate injection. Int J Gynaecol Obstet. 45:62–63. 1994. View Article : Google Scholar : PubMed/NCBI
17.	Rose SL, Kunnimalaiyaan M, Drenzek J and Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol Oncol. 117:130–133. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Chu D, Wang W, Xie H, et al: Notch1 expression in colorectal carcinoma determines tumor differentiation status. J Gastrointest Surg. 13:253–260. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Wang M, Wang J, Wang L, Wu L and Xin X: Notch1 expression correlates with tumor differentiation status in ovarian carcinoma. Med Oncol. 27:1329–1335. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Yoo J, Choi JY, Moon SH, et al: Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer. 22:1226–1233. 2012.
21.	Sorosky JI: Endometrial cancer. Obstet Gynecol. 120:383–397. 2012. View Article : Google Scholar
22.	Wang M, Wu L, Wang L and Xin X: Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780. Biochem Biophys Res Commun. 393:144–149. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Hopfer O, Zwahlen D, Fey MF and Aebi S: The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer. 93:709–718. 2005. View Article : Google Scholar
24.	Tsang RY, Al-Fayea T and Au HJ: Cisplatin overdose: toxicities and management. Drug Saf. 32:1109–1122. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Jones ME, van Leeuwen FE, Hoogendoorn WE, et al: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 14:R912012. View Article : Google Scholar : PubMed/NCBI
26.	Ma K, Wen HW and Liao QP: Expression of Notch3 and Notch intracellular domain in ovarian carcinoma and effect of N-[N-(3,5-difluorophenyl) acetyl-L-alanyl]-S-phenyl glycine t-butyl ester on ovarian carcinoma cell. Zhonghua Fu Chan Ke Za Zhi. 45:921–926. 2010.In Chinese.
27.	Ma XG, Wang YM, Xue FX, et al: Clinicalpathological characteristics of Lynch syndrome related epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 47:201–204. 2012.In Chinese.
28.	van den Akker T, Beltman J, Leyten J, et al: The WHO maternal near miss approach: consequences at Malawian District level. PLoS One. 8:e548052013.PubMed/NCBI
29.	Masuda S, Kumano K, Suzuki T, et al: Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Sci. 100:2444–2450. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Kohorn EI: Imaging practices in the diagnosis and management of gestational trophoblastic disease: an assessment. J Reprod Med. 57:207–210. 2012.PubMed/NCBI
31.	Sun XM, Wen HW, Chen CL and Liao QP: Expression of Notch intracellular domain in cervical cancer and effect of DAPT on cervical cancer cell. Zhonghua Fu Chan Ke Za Zhi. 44:369–373. 2009.In Chinese.
32.	Korsmeyer SJ: Regulators of cell death. Trends Genet. 11:101–105. 1995. View Article : Google Scholar
33.	Drexler HC: Programmed cell death and the proteasome. Apoptosis. 3:1–7. 1998. View Article : Google Scholar
34.	Ito M: Factors controlling cyclin B expression. Plant Mol Biol. 43:677–690. 2000. View Article : Google Scholar : PubMed/NCBI
35.	Friedrich K, Wieder T, Von Haefen C, et al: Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene. 20:2749–2760. 2001. View Article : Google Scholar : PubMed/NCBI
36.	Williams J, Lucas PC, Griffith KA, et al: Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol. 96:287–295. 2005. View Article : Google Scholar
37.	Beel AJ and Sanders CR: Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci. 65:1311–1334. 2008. View Article : Google Scholar : PubMed/NCBI